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Abstract
A likely key factor in the failure of a HIV-1 vaccine based on cytotoxic T lymphocytes (CTL) is the natural
immunodominance of epitopes that fall in variable regions of the proteome, which both increases the chance of epitope
sequence mismatch with the incoming challenge strain and replicates the pathogenesis of early CTL failure due to
epitope escape mutation during natural infection. To identify potential vaccine sequences to focus the CTL response on
highly conserved epitopes, the whole proteomes of HIV-1 clades A1, B, C, and D were assessed for Shannon entropy at
each amino acid position. Highly conserved regions in Gag (cGag-1, Gag 148–214, and cGag-2, Gag 253–331), Env (cEnv,
Env 521–606), and Nef (cNef, Nef 106–148) were identified across clades. Inter- and intra-clade variability of amino acids
within the regions tended to overlap, suggesting that polyvalent representation of consensus sequences for the four
clades would allow broad HIV-1 strain representation. These four conserved regions were rich in both known and
predicted CTL epitopes presented by a breadth of HLA types, and screening of 54 persons with chronic HIV-1 infection
revealed that these regions are commonly immunogenic in the context of natural infection. These data suggest that
vaccine delivery of a 16-valent mixture of these regions could focus the CTL response against conserved epitopes that
are broadly representative of circulating HIV-1 strains.
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Introduction
Efforts to design a vaccine against Human Immunodeficiency
Virus type 1 (HIV-1) have been disappointing. The principal
empirical strategies that yielded successful vaccines against other
viruses in the past have not provided protective immunity. The
first unsuccessful attempts included strategies using inactivated
whole virus or virus protein subunits, which would be expected to
raise antibodies and HLA class II-restricted helper responses
against HIV-1. When such approaches (including a phase III trial
of the HIV-1 envelope-based ‘‘AIDSVAX’’) failed to produce
protective humoral immunity, researchers turned to the idea that a
vaccine to elicit HLA class I-restricted cytotoxic T lymphocyte
(CTL) responses might provide protection against disease if not
infection, given the increasingly clearly protective role of CTL in
the immunopathogenesis of HIV-1 infection.
The attempts to generate HIV-1-specific CTL responses with a
vaccine have focused heavily upon vector development for
immunogenicity, as safety concerns precluded the classical empiric
approach of using live-attenuated HIV-1. Although numerous
strategies ranging from naked plasmid DNA to replication-competent
vaccinia vector showed promise in animal models, to date only
recombinant adenovirus serotype 5 (rAd5) has appeared to be reliably
immunogenic for CTL responses in humans. Vaccination of HIV-1-
uninfected persons with modified replication-incompetent rAd5
containing HIV-1 genes elicited CTL responses comparable to those
raised by natural HIV-1 infection, as measured by ELISpot and
intracellular interferon-c assays [1]. Unfortunately, the first large
efficacy trial of this approach was halted for futility at mid-enrollment,
when interim safety analysis revealed that there was no difference in
infection incidence or set-point viremia levels after infection between
placebo and vaccine arms [2].
The cause of vaccine failure remains unknown, but there are at
least two major types of possibilities (reviewed in [3,4]). First, the
‘‘immunogenicity’’ of the vaccine as reflected by IFN-c-based
assays using exogenously loaded small peptides as surrogates for
cellular HIV-1 infection may not have reflected true functional
immunogenicity for antiviral CTL, i.e. capability to recognize
levels of epitope on infected cells [5] or phenotype/effector/
trafficking capability of the CTL raised. While this has yet to be
investigated, the ability of the same rAd5 vector to elicit protective
immunity against SIV in the rhesus macaque model suggests that
immunogenicity from this vector may be adequate. Second, the
CTL targeting elicited by the vaccine may have been faulty in at
least two ways related to immunodominant targeting of variable
epitopes. Recent functional studies of CTL antiviral activity have
indicated that the impact of epitope variation has been greatly
underestimated by prior peptide-based assays [5,6]. The targeted
epitopes from the vaccine may not have matched the epitopes in
the circulating strain in this case. Another possibility is that
targeting of variable epitopes may have replicated natural mis-
direction of CTL immunodominance. In essence, the vaccine
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approach in the trial of rAd5 delivered genes for most of the HIV-
1 proteome (Gag, Pol, Nef), to mimic natural infection and whole
viral immunologic exposure. Presumably, this would give the host
similar choices for CTL targeting and result in immunodominance
patterns comparable to early natural infection.
While other successful vaccines have targeted viruses where
natural immunity is frequently protective if the host survives the
initial infection, natural immunity against HIV-1 infection
generally fails. Thus, mimicking naturally occurring immune
responses with a vaccine may not suffice for HIV-1, in contrast to
other viruses. Increasing data about early HIV-1 infection suggest
that CTL targeting initially is misdirected towards variable
epitopes [7,8], allowing early viral escape [9,10,11,12], and
inadequate early immune containment with resultant irreversible
depletion of the CD4+ T helper cell pool [13,14,15] that dooms
the efficacy of the CTL response in the long term despite eventual
re-targeting against conserved epitopes. A vaccine might therefore
offer the opportunity to alter the patterns of CTL immunodomi-
nance seen in natural infection by predetermining memory
responses against epitopes that are highly conserved, rather than
those with the highest affinity [16] or other immunodominant
properties that do not limit escape. Thus, some vaccine developers
have considered strategies to provide vaccine sequences to target
conserved epitopes, in contrast to the current standard approach
of delivering whole proteins (including variable regions). Here we
identify conserved regions within the HIV-1 proteome to propose
as vaccine sequences, with additional representation of intra- and
inter-clade variation.
Materials and Methods
Ethics Statement
The portion of this work involving human subjects was
performed under a protocol approved by the Office for Protection
of Human Research Subjects (IRB) at the University of California
Los Angeles. Written informed consent was received from each
participant.
HIV-1 sequences
All available (as of 7/21/08) full length protein sequences of
Gag, Pol, Env, Nef, Tat, Rev, Vif, Vpr, and Vpu, for clades A1/
A2, B, C, and D were downloaded from the Los Alamos National
Laboratory HIV Sequence Database at: http://www.hiv.lanl.gov/
components/sequence/HIV/search/search.html.
Determination of Shannon entropy across the HIV-1
proteome
Shannon entropy is a quantitative measurement of uncer-
tainty in a data set such as a collection of protein sequences.
Comparing the sequences against each other, the entropy of
each amino acid position reflects the uncertainty (variability) of
that position across all sequences. Lower entropy reflects more
predictability at that position, e.g. the amino acid is always the
same (no entropy), or few different amino acids observed rarely.
Higher entropy reflects more uncertainty at that position, e.g.
many different amino acids frequently occupy that position with
no predominant amino acid.
To calculate Shannon entropy across the HIV-1 proteome, the
sequences of each full length protein within each clade were
aligned against clade consensus protein sequences (Los Alamos
HIV Sequence Database) using Clustal 62.0.10 on an Apple
Macintosh Pro running OS 610.5.7, with manual editing.
Shannon Entropy at each amino acid position was then calculated
using the Shannon Entropy online tool at the Los Alamos National
Laboratory HIV Sequence Database: http://www.hiv.lanl.gov/content/
sequence/ENTROPY/entropy_one.html. (Further explanation is given at the
Los Alamos National Laboratory HIV Sequence Database: http://
www.hiv.lanl.gov/content/sequence/ENTROPY/entropy_readme.
html ).
Listing of known and predicted epitopes within regions
of the HIV-1 proteome
Known and predicted CTL epitopes within regions of the HIV-
1 proteome were listed using the Epitope Location Finder
program online tool at the Los Alamos National Laboratory
HIV Immunology Database (using all available class I HLA
types): http://www.hiv.lanl.gov/content/sequence/ELF/epitope_analyzer.
html.
The input amino acid sequences for epitope prediction were
HIV-1 2004 overall consensus sequences (‘‘consensus of consen-
sus’’) obtained from the Los Alamos National Laboratory
HIV Sequence Database: http://www.hiv.lanl.gov/content/sequence/
NEWALIGN/align.html.
Analysis of amino acid variation within clades
The frequencies of amino acid polymorphisms at specific
locations within each clade were assessed using the online
QuickAlign tool from the Los Alamos National Laboratory HIV
Sequence Database: http://www.hiv.lanl.gov/cgi-bin/QUICK_ALIGN/
QuickAlign.cgi.
HIV-1-infected participants
Persons with chronic HIV-1 infection who were not on
antiretroviral therapy were recruited through a University of
California Los Angeles IRB-approved protocol. PBMC were
isolated from freshly drawn whole blood by ficoll-hypaque
gradient and viably cryopreserved. Plasma viremia data were
obtained from medical records (or patient self-report in a few cases
where medical records were not available).
Mapping of HIV-1-specific CTL responses
Standard interferon-c ELISpot assays were performed using
polyclonally expanded CD8+ T cells as previously described in
detail [17]. In brief, PBMC were thawed and cultured with a
CD3:CD4 bi-specific monoclonal antibody, resulting in expansion
of CD8+ T cells (generally at least 95% CD3+CD8+) that has been
shown to mirror CTL responses in unexpanded CD8+ T cells
[17,18]. After 14 days, the cells were utilized for standard ELISpot
assays using overlapping peptides (15 amino acids sequentially
overlapping by 11 amino acids) from the NIH AIDS Reference
and Research Reagent Repository. Gag peptides included clade B
consensus and DU422 sequences (catalog #8117 and #6869).
Env peptides included clade B consensus or MN sequences
(#9480 and #6451). Nef peptides included clade B consensus
sequences (#5189). Pools of 16 or fewer peptides were utilized for
a first round of screening, followed by 464 matrices to identify
individual peptide candidates for a second round of screening,
followed by confirmation of individual peptides in a third round of
screening.
Results
Despite the overall variability of the HIV-1 clade B
proteome, there are stretches of relatively conserved
sequences
The plasticity of HIV-1 sequences is an obvious barrier
for vaccine development. To assess sequence variability and
HIV-1 Vaccine Sequences
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conservation across the viral proteome, all available clade B
complete HIV-1 protein sequences in the Los Alamos National
Laboratory (LANL) HIV Sequence Database were assessed for
Shannon entropy at each amino acid position. The entropy at
each position and the mean entropy for each stretch of nine amino
acids (corresponding to most potential epitopes) were plotted for
each of the nine viral proteins (Figure 1). The plot revealed gross
differences between proteins, such as generally higher variability in
Env and relatively lower variability in Pol. All proteins contained
spikes of variable codons scattered throughout, although there
were stretches of lower variability with fewer spikes even in the
generally more variable proteins Env and Nef. These plots
therefore demonstrated that despite the overall plasticity of the
HIV-1 proteome, there are sequence constraints that constrict
variability in certain regions within several proteins. Four regions
from highly expressed proteins (i.e. excluding Pol) that were at
least 40 amino acids in length and generally conserved were
selected for further examination (Figure 1 shaded regions). Pol was
excluded due to its low level of expression from translation
requiring a ribosomal frameshift along the gag-pol transcript [19],
which can reduce the immunogenicity and antiviral efficacy of
Pol-specific CTL [20,21].
Sequence constraints fall in the same regions across
different HIV-1 clades, and within selected conserved
regions, inter-clade variability is limited to consistent
sites
HIV-1 is observed in genetically distinct clades that reflect
divergent pathways for evolution [22]; clades A (A1), B, C, and D
reflect the vast majority of circulating strains worldwide. To assess
whether the patterns of sequence variability observed for clade B
(Figure 1) apply to other clades, the entropy for available clade A1,
C, and D HIV-1 complete protein sequences in the LANL HIV
Sequence Database were analyzed in parallel for Shannon entropy
at each amino acid position. Comparisons of the clades revealed
that the patterns of variability across the proteome were very
similar in general (Figure 2 and data not shown), suggesting that
Figure 1. Shannon Entropy across the HIV-1 clade B proteome. All full length clade B protein sequences in the LANL HIV Sequence Database
were aligned and assessed for Shannon entropy of each amino acid position. The red bars indicate entropy at each codon, and the heavy black lines
plot mean entropy for the nine amino acids starting at each position. The shaded regions indicate relatively conserved regions that were examined
further. Note that the numbering of the conserved regions (based on HXB2 position) does not necessarily match amino acid positions in the graphs
(due to insertions in some sequences relative to HXB2).
doi:10.1371/journal.pone.0007388.g001
HIV-1 Vaccine Sequences
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different HIV-1 clades share certain areas of functional/structural
constraint despite divergent evolution. Examining the four selected
conserved regions, it was notable that differences between clade
consensus sequences in these regions were limited to a few codon
positions (Figure 3). This finding further suggested that inter-clade
variability in these conserved regions is relatively limited, with a
few wobble positions that have diverged between clades.
Within conserved regions of the HIV-1 proteome, much
of the intra-clade diversity overlaps inter-clade sequence
variation
Within the four selected conserved regions, there remained
amino acid positions that are somewhat variable within each
clade. The variability in these regions was assessed in further detail
for clades A1-D (Figures 4, 5, 6, 7 and Tables 1, 2, 3, 4). Plotting
the entropy of each amino acid position (Figures 4–7) within each
clade demonstrated that many of the positions that were more
variable intra-clade overlapped positions where the consensus
sequence differed inter-clade. Furthermore, at these varying
positions within each clade, there often was a single dominant
non-consensus polymorphism that corresponded to the consensus
amino acid for another clade. For example, in region cGag-1, the
consensus amino acid at position 159 was isoleucine for clades A1,
C, and D, and valine for clade B. Within clades A1, C, and D,
position 159 often varied from consensus, and the most common
polymorphism was valine. Conversely for clade B, position 159
also frequently varied from consensus, and the most common
polymorphism was isoleucine. These observations suggested that
there is a high degree of overlap between intra-and inter- clade
variability in these conserved regions, consistent with a recent
study examining HIV-1 sequence variation [23]. Thus a mixture
of clade consensus sequences of these conserved regions (to
represent HIV-1 variability worldwide) would represent a large
portion of circulating HIV-1 sequences within any clade (to
represent HIV-1 variability within individuals).
The selected conserved regions are rich in potential CTL
epitopes
To assess whether these regions might be immunogenic if
delivered in a CTL-based vaccine, the Los Alamos HIV
Immunology Database was scanned for known and predicted
CTL epitopes falling within the regions (Table 5). Each region
contained many previously reported CTL epitopes associated with
a variety of HLA types, as well as binding motifs for many
additional HLA types. These findings suggested that these
conserved regions contain many epitopes that can be presented
by a broad range of HLA types, and therefore should be
immunogenic for CTL responses from most persons.
The selected conserved regions are immunogenic in
natural infection
To assess this prediction and test whether the selected conserved
regions are indeed commonly immunogenic in actual HIV-1
infection, the CTL responses within 54 persons in the Los Angeles
Figure 2. Entropy of 9 amino acid stretches for clades A1-DofHIV-1. Shannon entropy was assessed for full length protein sequences of clades A1,
C, and D available from the LANL HIV Sequence Database, as in Figure 1. For each clade, the mean entropies of nine amino acid stretches are plotted for
each clade for the proteins containing the relatively conserved regions (shaded) identified in Figure 1. Note that the numbering of the conserved regions
(based on HXB2 position) does not necessarily match amino acid positions in the graphs (due to insertions in some sequences relative to HXB2).
doi:10.1371/journal.pone.0007388.g002
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area with chronic infection (not receiving antiretroviral treatment)
were examined. HIV-1-specific CTL responses were defined by
standard interferon-c ELISpot assays using proteome-spanning
15-mer peptides overlapping by 11 amino acids. All four regions
were targeted by CTL within multiple persons (Table 6). The least
often recognized was the Env region, where responses were seen in
4/54 persons (7.4%). The two Gag and Nef regions were each
targeted similarly in frequency, at 17/54 (31.5%), 17/54 (31.5%),
and 19/54 (35.2%) respectively. Across the group, 38/54 (70.4%)
of persons targeted at least one region, 17/54 (31.5%) targeted at
least two regions, 2/54 (3.7%) targeted at least three regions, and
none was observed to target all four regions. Although these
subjects were enriched for HLA B*57 due to the bias of selecting
untreated persons, the presence or absence of B*57 did not appear
to predict responsiveness against these regions. Correlations
between targeting of these conserved regions to viremia were not
observed in this relatively small number of subjects (not shown).
Overall, these data confirmed that these conserved regions can be
immunogenic in the context of whole HIV-1 infection, suggesting
that CTL responses could be focused preferentially on these
regions by an exclusive vaccine.
Discussion
While a CTL based vaccine may not prevent HIV-1 infection, it
may offer the opportunity to attenuate disease from subsequent
infection. To do so, however, the CTL responses generated by the
vaccine must surpass the efficacy of those that would be raised in
the natural course of infection. Simply priming CTL responses to
have a head start versus HIV-1 infection and immune damage
could be advantageous, but the recent failure of an apparently
immunogenic CTL-based vaccine to have any impact on viremia
set-point [2] suggests that this is not sufficient. Clearly, the
interaction between CTL and HIV-1 during acute HIV-1
infection is crucial, because set-point viremia (which predicts the
long term rate of disease progression) is determined by the end of
acute infection, and is maintained in large part by the CTL
response [24,25,26]. Given the tendency of this response to target
variable epitopes and the observation of rapid and frequent viral
escape during acute infection (when massive depletion of crucial
helper CD4+ T cells occurs), use of a vaccine to focus the response
selectively against highly conserved epitopes may offer an avenue
to address a key shortcoming of the natural immune response. The
other key advantage of such targeting would be minimizing the
chance that the epitope sequences of the vaccine would mis-match
those of an incoming challenge strain of HIV-1.
Despite the overall plasticity of the HIV-1 proteome, viral
variability is not limitless. Its protein sequences clearly are
constrained in particular domains, which is not surprising given
the many structure/function requirements for viral replication that
are imposed on the small proteome. Shannon entropy analysis
reveals stretches that are apparently highly constrained in
variability and therefore may be useful for CTL focusing by a
vaccine. While these regions were selected purely on the basis of
entropy analysis, it is interesting that they closely correspond to
distinct functional domains in Gag, Env, and Nef. The cGag-1 and
cGag-2 sequences both fall in the p24 capsid; the former spans
four a-helices that are absolutely required for viability, and the
latter spans the so-called ‘‘major homology region’’ that is
structurally conserved across other diverse lentiviruses such Feline
Immunodeficiency Virus, Rous Sarcoma Virus, Murine Mamma-
ry Tumor Virus, Bovine Leukemia Virus, Friend Murine
Leukemia Virus, and HTLV-1 [27]. The cEnv region falls in
the ectodomain of gp41 and spans the functionally crucial fusion
peptide and hepatad repeats [28]. The cNef region falls in the
‘‘central conserved region’’ and includes the second alpha helix
(key for interaction with the src kinase SH3) and the three adjacent
beta strands that compose the central structured core domain [29],
and thus contains a key binding site required for many cellular
effects of Nef, and sequences that are a crucial structural scaffold.
Figure 3. Sequences of relatively conserved regions of the HIV-1 proteome. The relatively conserved regions shaded in Figures 1 and 2 are given
for clades A1, B, C, and D, aligned against the overall consensus across all group M clades. ‘‘-’’ indicates amino acid identity with overall consensus.
doi:10.1371/journal.pone.0007388.g003
HIV-1 Vaccine Sequences
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Within these generally conserved regions, the remaining
variability tends to occur at a few amino acid positions, further
reflecting the strict functional restrictions for sequence variation.
Much of the intra-clade variability overlaps that of the inter-clade
variability of these sequences, suggesting that there are limited
choices for amino acid substitutions in a few foci of ‘‘wobble’’
Figure 4. Shannon entropy in the conserved region cGag-1. For HIV-1 Gag amino acids 148–214, Shannon entropies of individual codons (red bars)
and average entropies of stretches of 9 codons (black lines) are plotted for clades A1–D. The shaded columns indicate positions where the consensus
sequences differ between clades. For each of those positions, the consensus amino acid and most common variant (in parentheses) are indicated.
doi:10.1371/journal.pone.0007388.g004
HIV-1 Vaccine Sequences
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within the context of locally rigid functional/structural constraints.
Thus, designing a vaccine to represent the polymorphisms seen in
the most common clades of HIV-1 serves two advantages of
allowing the vaccine to represent the variability between viral
species across geographic regions (different clades) and within
individuals (genetic drift).
Figure 5. Shannon entropy in the conserved region cGag-2. For HIV-1 Gag amino acids 250–335, Shannon entropies of individual codons (red
bars) and average entropies of stretches of 9 codons (black lines) are plotted for clades A1–D. The shaded columns indicate positions where the
consensus sequences differ between clades. For each of those positions, the consensus amino acid and most common variant (in parentheses) are
indicated.
doi:10.1371/journal.pone.0007388.g005
HIV-1 Vaccine Sequences
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These conserved regions therefore could be utilized in a
polyvalent vaccine. A mixture of clades A1-D consensus sequences
for each of the four regions would provide highly conserved
epitopes, and include the most common variants of epitopes
spanning the few ‘‘wobble’’ positions that vary intra- and inter-
clade. Delivering these regions separately (in a mixture of 16
individual vectors) rather than concatenating them into a single
construct, could be advantageous for preventing competition
Figure 6. Shannon entropy in the conserved region cEnv. For HIV-1 Env amino acids 521–606, Shannon entropies of individual codons (red bars)
and average entropies of stretches of 9 codons (black lines) are plotted for clades A1–D. The shaded columns indicate positions where the consensus
sequences differ between clades. For each of those positions, the consensus amino acid and most common variant (in parentheses) are indicated.
doi:10.1371/journal.pone.0007388.g006
HIV-1 Vaccine Sequences
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between epitopes and yield a broader response [30,31,32]. While
providing the four consensus versions of each region may help
represent the breadth of polymorphisms in these overall conserved
sequences, another benefit may be dilution of less common
variants. An epitope sequence that is conserved in all four
consensus sequences will be expressed at four-fold the level of an
Figure 7. Shannonentropy in the conserved region cNef. For HIV-1 Nef amino acids 106–148, Shannon entropies of individual codons (red bars) and
average entropies of stretches of 9 codons (black lines) are plotted for clades A1–D. The shaded columns indicate positions where the consensus sequences
differ between clades. For each of those positions, the consensus amino acid and most common variant (in parentheses) are indicated.
doi:10.1371/journal.pone.0007388.g007
HIV-1 Vaccine Sequences
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Table 1. Varying consensus sequences and common polymorphisms in cGag-1.
159 173 186 190 203
CLADE A1 Consensus I (90.4%) S (91.2%) M (85.5%) I (87.2%) D (95.2%)
Polymorphism #1 V (9.6%) T (7.2%) T (8.9%) V (8.8%) E (4.8%)
Other T (2.4%)
CLADE B Consensus V (79.4%) S (84.5%) T (99.1%) T (99.4%) E (96.5%)
Polymorphism #1 I (20.5%) T (14.8%) L (0.4%) A (0.3%) D (3.5%)
CLADE C Consensus I (90.7%) T (95.6%) T (95.6%) T (97.8%) D (99.0%)
Polymorphism #1 V (9.1%) S (3.4%) S (3.2%) A (1.4%) E (1.0%)
CLADE D Consensus I (96.2%) S (65.8%) T (88.5%) T (94.9%) E (96.2%)
Polymorphism #1 V (3.8%) T (30.4%) S (6.4%) A (2.5%) D (3.8%)
At each position in cGag-1 (Gag 148–214) where consensus amino acids differ between clades, the frequency of the consensus amino acid and the most common
polymorphism(s) within each clade are listed (based on all available whole protein sequences in the LANL HIV Sequence Database).
doi:10.1371/journal.pone.0007388.t001
Table 2. Varying consensus sequences and common polymorphisms in cGag-2.
260 280 286 301 310 312 319
CLADE A1 Consensus D (88.7%) V (97.6%) K (78.4%) F (99.2%) T (87.1%) E (68.0%) E (79.8%)
Polymorphism #1 E (10.5%) T (1.6%) R (21.0%) Y (0.8%) S (12.9%) D (32.3%) D (19.4%)
CLADE B Consensus E (92.4%) T (73.0%) R (75.3%) Y (99.7%) S (91.0%) E (69.5%) E (99.7%)
Polymorphism #1 D (7.4%) V (18.0%) K (24.7%) - T (8.9%) D (30.5%) K (0.2%)
Other S (3.6%) I (3.4%)
CLADE C Consensus D (68.5%) V (97.5%) K (60.1%) F (99.8%) T (96.6%) D (70.1%) D (80.5%)
Polymorphism #1 E (31.0%) T (1.7%) R (39.6%) Y (0.2%) S (3.1%) E (29.6%) E (18.8%)
CLADE D Consensus E (91.1%) V (98.7%) R (83.5%) Y (97.5%) S (91.1%) D (72.2%) E (97.5%)
Polymorphism #1 D (7.6%) I (1.3%) K (16.5%) L (1.3%) T (8.9%) E (26.6%) D (2.5%)
At each position in cGag-2 (Gag 250–335) where consensus amino acids differ between clades, the frequency of the consensus amino acid and the most common
polymorphism(s) within each clade are listed (based on all available whole protein sequences in the LANL HIV Sequence Database).
doi:10.1371/journal.pone.0007388.t002
Table 3. Varying consensus sequences and common polymorphisms in cEnv.
500 518 530 532 543 545 548 567
CLADE A1 Consensus I (73.2%) S (83.1%) L (88.7%) K (82.9%) A (100%) V (95.8%) V (90.1%) L (97.2%)
Polymorphism #1 V (14.1%) N (15.5%) M (9.9%) R (15.5%) - I (2.8%) L (7.0%) I (2.8%)
Other M (7.0%)
CLADE B Consensus M (27.8%) N (84.2%) L (73.7%) Q (97.4%) A (99.7%) V (89.8%) V (91.0%) L (96.4%)
Polymorphism #1 I (26.3%) S (10.5%) M (24.7%) R (1.4%) - I (7.4%) L (3.8%) I (1.5%)
Other V (23.7% R (4.8%) I (1.2%) K (0.9%) L (2.8%) I (3.6%)
CLADE C Consensus I (85.5%) S (86.1%) M (79.8%) Q (99.6%) T (45.9%) V (97.5%) I (82.9%) L (91.2%)
Polymorphism #1 M (7.3%) N (13.3%) L (19.8%) K (0.4%) A (53.9%) I (2.2%) L (8.4%) I (3.3%)
Other V (4.3%) V (2.2%)
CLADE D Consensus M (15.3%) N (91.8%) L (94.1%) Q (100%) A (100%) I (40.5%) V (94.1%) H (90.6%)
Polymorphism #1 L (57.6%) S (4.7%) M (5.9%) - - V (57.1%) L (3.5%) L (7.1%)
Other V (17.6%) I (8.2%)
At each position in cEnv (Env 521–606) where consensus amino acids differ between clades, the frequency of the consensus amino acid and the most common
polymorphism(s) within each clade are listed (based on all available whole protein sequences in the LANL HIV Sequence Database).
doi:10.1371/journal.pone.0007388.t003
HIV-1 Vaccine Sequences
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epitope variant that is present in only one consensus sequence.
Although such a polyvalent approach may be cumbersome
logistically, there is ample precedent for polyvalent vaccines
against other pathogens such as Streptococcus pneumoniae [33] and
Human Papilloma virus [34].
Other groups also have devised differing strategies for including
highly conserved epitopes in CTL-based vaccines. Rolland et al
identified stretches of 8 or more amino acids selected to be highly
conserved across the entire M-group for use as a peptide-based vaccine
[35]. This approach identified 46 peptides (listed as ‘‘first tier’’ peptides
in: http://www.mullinslab.microbiol.washington.edu/HIV/Rolland
2007/Rolland2007-supplement_files/SuppFigs.html#S1), but most
of these do not correspond to known epitopes, and ten consist of
eight amino acid sequences (unlikely to contain epitopes, which are
usually nine amino acids). Thus, this approach may be too stringent to
provide the breadth of epitopes required to cover a breadth of HLA
types, and additionally faces the difficulty that peptide-based vaccines
generally have had poor immunogenicity in humans. More similar to
our proposed strategy, Letourneau et al [36] screened for stretches of
conserved sequences, identifying 14 candidate proteome regions that
are relatively conserved. As a vaccine candidate, they concatenated
these into a monovalent linear genetic construct, and alternated clade
A–D consensus sequences for each consecutive region in an attempt to
minimize clade bias. In contrast to our proposed polyvalent vaccine,
this approach may not adequately account for intra- and inter-clade
polymorphisms within the conserved sequences, because each stretch
represents the sequence of only one clade. Concatenation of the 14
regions also could yield unwanted spurious epitopes at the 13 sites of
splicing, although testing of this strategy in transgenic human A*02
mice suggested that it can be immunogenic for proper A*02-restricted
CTL responses.
The utility of our proposed strategy depends on the hypothesis
that vaccine delivery of the selected sequences will steer the early
CTL response towards highly constrained epitopes that do not
Table 4. Varying consensus sequences and common polymorphisms in cNef.
108 116 120 133 135 144
CLADE A1 Consensus E (75.0%) N (50.7%) Y (63.7%) T (40.4%) F (40.3%) K (98.5%)
Polymorphism #1 D (24.3%) H (49.3%) F (34.1%) I (39.0%) Y (59.7%) E (1.5%)
Other V (18.4%)
CLADE B Consensus D (83.0%) H (84.7%) Y (84.6%) I (52.4%) Y (70.1%) K (99.3%)
Polymorphism #1 E (16.5%) N (15.1%) F (15.0%) T (22.8%) F (27.4%) R (0.3%)
Other V (22.3%) W (1.5%)
CLADE C Consensus E (76.9%) H (62.1%) Y (44.0%) V (85.8%) Y (81.4%) K (99.5%)
Polymorphism #1 D (22.7%) N (37.4%) F (54.7%) I (8.1%) F (12.9%) -
CLADE D Consensus E (53.5%) N (35.4%) F (30.3%) I (72.4%) Y (96.0%) E (83.7%)
Polymorphism #1 D (46.5%) H (64.6%) Y (64.6%) V (13.3%) F (3.0%) K (9.2%)
Other I (5.1%) T (12.2%) Q (7.1%)
At each position in cNef (Nef 106–148) where consensus amino acids differ between clades, the frequency of the consensus amino acid and the most common
polymorphism(s) within each clade are listed (based on all available whole protein sequences in the LANL HIV Sequence Database).
doi:10.1371/journal.pone.0007388.t004
Table 5. Known and potential epitopes in the conserved regions.
Region Reported Epitopes (LANL Database) Potential Epitopes For Other HLA Types
cGag-1 A*02, A*11, A*25, A*26 A*03, A*20, A*30, A*31, A*32, A*33, A*68, A*69
B*04, B*07, B*14, B*15, B*27, B*35, B*38, B*39, B*40, B*42,
B*44, B*45, B*52, B*53, B*81
B*08, B*18, B*37, B*46, B*51, B*54, B*55, B*56, B*67, B*78
C*01, C*06, C*08 C*03, C*04, C*06, C*07
cGag-2 A*02, A*11, A*24, A*26, A*33 A*03, A*25, A*29, A*30, A*31, A*66, A*68, A*69
B*07, B*08, B*14, B*15, B*18, B*27, B*35, B*44, B*52, B*53,
B*57, B*58, B*70, B*71, B*81
B*37, B*38, B*39, B*40, B*46, B*48, B*51, B*54, B*55, B*56, B*67, B*78
C*03, C*04, C*05, C*08, C*18 C*06, C*07, C*12, C*14, C*16
cEnv A*02, A*11, A*23, A*24 A*03, A*25, A*26, A*29, A*30, A*31, A*33, A*66, A*68, A*69
B*08, B*14, B*27, B*51, B*58 B*07, B*15, B*18, B*35, B*37, B*38, B*39, B*46, B*48, B*52, B*78
C*03, C*07, C*08, C*12, C*15 C*01, C*02, C*05, C*06, C*16, C*17, C*18
cNef A*01, A*02, A*03, A*23, A*24, A*29, A*33, A*69 A*11, A*25, A*26, A*30, A*31, A*66, A*68
B*07, B*13, B*15, B*18, B*27, B*35, B*37, B*42, B*49, B*53, B*57 B*38, B*39, B*40, B*44, B*46, B*51, B*54, B*55, B*56, B*58, B*67, B*78
C*04, C*06, C*07 C*03, C*14
For each region, HLA types for which there are reported and predicted epitopes in the Los Alamos HIV Immunology Database (http://www.hiv.lanl.gov/content/
sequence/ELF/epitope_analyzer.html) are listed. Types in bold font are those in the database that have been reviewed as best defined optimal epitopes [42].
doi:10.1371/journal.pone.0007388.t005
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Table 6. Recognition of conserved regions by CTL responses in persons with chronic HIV-1 infection.
ID VL HLA A HLA B HLA C cGag1 cGag2 cEnv cNef Min# Epitopes
1 Y *02/*03 *07/*35 *04/*07 0
5 Y *02/*24 *44/*55 *03/*05 6820/6821 1
6 Y *01/*02 *08/*35 *04/*07 6811 1
7 N *29/*68 *44/*53 *04/*16 6791/6797 6823 5171/5172 4
9 Y *03/*26 *15/*38 *03/*12 6784/6788/7912/7913
7920
6813/6814/6820/6821
7938/7939/7944/7945
8900/8901 4
10 N *01/*25 *18/*57 *06/*12 6787/6788/6789/6797 5167 4
11 Y *01/*11 *35/*57 *04/*06 0
12 N *30/*34 *53/*57 *03/*08 6787/6797 5167/5168 3
14 Y *03/*25 *18/*57 *07/*12 6787 1
15 Y *02/*03 *15/*56 *01/*03 0
16 Y *03/*32 *18/*40 *02/*07 0
17 Y *02/*03 *44/*51 *04/*14 6787/7911/7912 5168 2
18 Y *03/*68 *55/*57 03/*06 6797 5167 2
19 Y *02 *44/*50 *06/*16 0
21 Y *02/*36 *53 *04 5171/5172 1
22 Y *02/*32 *07/*15 *03/*07 5172 1
23 Y *03/*33 *44/*57 *03/*08 0
24 N *02 *13/*15 *06/*07 6349 1
25 Y *02/*03 *15/*40 *02/*03 6813/6814 5168 2
26 Y *01/*02 *08/*44 *05/*07 6811/6814/6815/7940 2
27 Y *03/*66 *35/*49 *04/*07 0
28 Y *03/*33 *07/*65 *07/*08 7946 8900 2
29 N *29/*31 *48/*56 *01/*08 7919/7920 1
30 Y *30 *08/*81 *07/*18 6812 5167/5168/5170/5171 3
31 Y *02 *13/*15 *03/*06 0
32 Y *03/*68 *08/*57 *06/*07 7911/7912 1
33 Y *01/*74 *49/*53 *04/*07 5171/5172 1
34 Y *11/*30 *52/*57 *07/*12 6787 6823/6824/7949/7950 2
35 Y *01/*23 *07/*44 *04/*07 5169/5171 2
36 Y *02/*11 *39/*57 *06/*07 0
37 Y *25/*33 *14/*38 *08/*12 0
39 Y *31/*32 *12/*35 *04/*06 0
40 Y *02/*31 *35/*44 *04/*05 5169 1
41 Y *11/*31 *13/*52 *04/*12 0
44 Y *02/*11 *07/*15 *03/*07 7938/7939 1
45 Y *30/*68 *15 *02/*03 6820 1
46 N *25/*68 *35/*14 *04/*08 6792/7915/7916 5168/5169/5171/5172 3
47 Y *11/*33 *55/*78 *03/*16 0
48 N *24/*30 *15/*27 *01/*02 6812/6813 1
49 Y *02/*26 *38/*44 *07/*12 7919/7920 1
50 Y *24/*30 *38/*44 *05/*12 8907/8908 5171/5172 2
51 Y *02/*24 *14/*49 *07/*08 7944/7945/7946 5167/5169 4
52 Y *01/*25 *18/*57 *06/*12 6797/7911/7912 5171 3
54 Y *29/*74 *50/*81 *06/*18 6793/7915/7916 6814/6815 2
58 N *02/*29 *44/*15 *03 0
59 Y *02/*26 *44/*52 *03/*04 7912/7913 1
60 N *30 *07/*57 *15/*18 0
65 N *34/*74 *53/*57 *04/*07 6787/6788/7911/7912 5171/5172 2
66 Y *02/*23 *07/*45 *07/*16 5166/5168/5170/5172 4
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allow escape. While the determinants of effective CTL targeting
remain hypothetical, increasing data suggest that highly conserved
epitopes in highly expressed proteins are advantageous. Across
large numbers of persons, targeting of Gag, a highly expressed and
relatively conserved protein that should therefore yield epitopes
that are highly expressed and conserved compared to epitopes
from other proteins on average, has been shown to trend with better
immune control [37,38,39,40]. Additional studies on cohorts large
enough to power statistical dissections of individual epitope
contributions (rather than protein targeting in general) to set-
point viremia have begun to suggest reveal epitopes that are
associated with better immune containment. Recent data [41]
correlated CTL targeting against six epitopes to a beneficial effect
in lowering viremia in a cohort of chronically-infected persons.
Interestingly, when results of the STEP trial were analyzed,
vaccine-induced targeting of any of these epitopes also was
associated with lower viremia set-point in persons who had
subsequent HIV-1 infection. Of note, four of these six epitopes fall
in our proposed vaccine regions (which were designed before these
associations were reported): two in cGag-2 (KRWIILGLNK, Gag
263–272, and DRFFKTLRA, Gag 298–306) and two in cNef
(HTQGYFPDW, Nef 116–124, and LTFGWCFKLV, Nef 137–
146). These data suggest that our sequences have been selected
based on properties that yield advantageous epitopes (although all
advantageous epitopes do not necessarily fall in these regions).
The optimal vector system and viral sequences to be delivered
remain to be determined in HIV-1 vaccine development. Our
described sequences are proposed for the latter, given the high
degree of sequence conservation and immunogenicity in natural
HIV-1 infection. About 70% of persons had detectable responses
against at least one of the four regions, suggesting that a sizeable
proportion of the general population have HLA types that would
allow immunogenicity. A vaccine containing only these regions
could have a higher response rate, because it is likely that in
natural infection, potentially recognized epitope responses against
these regions are masked by the immunodominance of other
epitopes outside these regions, and possibly limited by ‘‘original
antigenic sin.’’ It is also unclear whether the four chosen regions
are equally immunogenic; only about 7% of persons with chronic
infection responded against cEnv, while cGag-1, cGag-2, and cNef
had similar response rates of about 32 to 35%. This agreed with
the lesser number of previously reported epitopes in cEnv
compared to the other regions. The number of predicted epitopes
in cEnv was similar, however, suggesting that there might be some
intrinsic reason for reduced immunogenicity of Env due to some
factor such as protein trafficking and accessibility to the class I
antigen pathway.
In conclusion, we have identified highly conserved regions of
the HIV-1 proteome that exhibit few variable amino acids. These
regions appear to be reasonably immunogenic in natural infection.
Representation of inter-clade variability within these regions
allows coverage of much of the intra-clade variability at those
positions. These data support the consideration of polyvalent
mixtures of these sequences as vaccine inserts to pre-set memory
CTL responses against highly conserved epitopes, thereby
favorably altering the immunodominance pattern in subsequent
natural infection.
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